Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA and/or Anti-CD19 CAR-T in Relapsed Multiple Myeloma
NCT03767725Phase 1Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-BCMA CAR-T and autologous anti-CD19 CAR-T cells in multiple myeloma (MM), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Dose-limiting toxicity at 5 months. Status: unknown.
02
Drugs
anti-BCMA CAR-Tautologous anti-CD19 CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03767725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767725.